CORONAVIRUS
COVID-19 – an intranasal lentiviral vaccine in development provides significant protection in animals
In a preprint on BioRxiv, scientists from the Pasteur-TheraVectys joint lab have disseminated animal test results for an intranasal, lentiviral vector-based COVID-19 vaccine. This study demonstrates that the vaccine candidate induces very high antibody production and strong cell-mediated response, while also drastically reducing lung viral loads. This work proves that an efficacious vaccine for SARS-CoV-2 must provide vaccine protection in the upper respiratory tract through which the virus enters the body.